Ready to FLIP THE SCRIPT? How to Prescribe IBSRELA

Wave Divider

Treatment for IBS-C Is Not One Size Fits All. When Your Patients Aren’t Getting Adequate Relief, Try a Therapy With a Different Mechanism of Action in a Different Class1,2

IBSRELA is dosed as one (1) 50-mg tablet BID

INSTRUCT patients as follows2:
check mark Take IBSRELA immediately prior to breakfast or the first meal of the day and immediately prior to dinner
check mark If a dose is missed, skip the missed dose and take the next dose at the regular time
check mark Do not take 2 doses at the same time

Get Started

IDENTIFY IBS-C patients who may benefit from IBSRELA
check mark Adult patients with a diagnosis of IBS-C (ICD-10: K58.1)2*
PRESCRIBE IBSRELA
check mark e-Prescribe to our specialty pharmacy partner, Transition Pharmacy, in Trevose, Pennsylvania
OR
check mark Use a specialty pharmacy that your office already works with and that will fully support and fill IBSRELA
*The ICD-10 code is provided for informational purposes only. It is the treating physician’s responsibility to determine the proper diagnosis, treatment, and applicable ICD-10 code. Ardelyx, Inc. does not guarantee coverage or reimbursement for the product.

Add Transition Pharmacy in Trevose, Pennsylvania as a favorite in your electronic health record system to save time when writing your next prescription.

ARE YOUR PATIENTS READY TO FLIP THE SCRIPT? ASK THEM, “DO YOU WANT TO TRY SOMETHING DIFFERENT?”
Ibsrela co-pay card
Terms and conditions apply. Copay is unavailable to government beneficiaries.

ArdelyxAssistTM Offers Several Programs to Support Patient Affordability

  • Commercially insured patients can pay as little as $0 per prescription through the IBSRELA copay program
  • ArdelyxAssist offers additional programs for eligible patients who are uninsured or underinsured and are unable to afford IBSRELA

ArdelyxAssist is here to help. Call us at 844-427-7352, option 1, if you have any questions or need support with IBSRELA access or affordability.

To fax a prescription: (877) 765-7664.

Resources for You and Your Patients

Commercial Copay Card Download copay card
Sample Letter of Medical Necessity Download template

Peer Perspectives

“The majority of my patients report they are happy with IBSRELA and want to continue on the medication.”

—Dr Jignesh Shah

Compensated advisor to Ardelyx
References:

1. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759-6773. 2. IBSRELA [prescribing information]. Waltham, MA: Ardelyx, Inc.; 2022.

INDICATION

IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

  • IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS

Risk of Serious Dehydration in Pediatric Patients

  • IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
  • Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea

Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

Please see full Prescribing Information, including Boxed Warning, for additional risk information.